Blsi

Prous Science Drug News & Perspectives
FILE DESCRIPTION
developments in drug therapy, highlighting new The Prous Science Drug News & Perspectives
generation compounds with therapeutic gains over database, produced by Prous Science Publishers, existing drugs and new therapeutic entities arising allows quick and easy consultation of the latest drug from innovative approaches to drug research.
news. The Prous Science Drug News & Perspectives Coverage: January 1988 - March 2004.
database contains all articles and texts published from selected sections (see Subject Coverage) of the printed The full-text entries in the Prous Science Drug News journal, Prous Science Drug News & Perspectives , plus unpublished records from the journal's sections: "Line Extensions," "R&D Briefs," and "People on the conferences, company communications, and scientific Move." Unpublished records, omitted from the printed "unpublished" and do not have volume, issue, or pagenumbers. Unpublished records may also include those DIALOG FILE DATA
in preparation for print. These records will have volume, issue and page numbers added in a later January 1992 to 2005 (see "Subject Coverage" for coverage dates for each journal section).
Update Frequency: ClosedFile Size: 33,888 records as of November 2005 SUBJECT COVERAGE
The Prous Science Drug News & Perspectives
database contains the following journal sections: Prous Science Drug News & Perspectives is producedby Prous Science Publishers. Questions concerning • Discovery Line. A look at efforts in new drug
file content should be directed to:Prous Science • Licensing Line. Short summaries on new
technology for licensing from various public and private sources. Coverage: January 1995 - • Line Extensions. New uses, combinations and
formulations of known drugs, including those launched and under development. Coverage: April • New Product Intros. New products recently
launched on their first markets, including genericand brand names, action, indication, presentation,and source. Coverage: March 1995 - March 2004.
• People on the Move. Organizational and personnel
changes in the pharmaceutical industry. Coverage:January 1993 - November 1998.
• R&D Briefs. Information on products progressing
through the drug discovery and developmentpipeline throughout the world. Coverage: January1992 - June 2005.
• The Year's New Drugs. Annual articles that offer
a historical and research perspective on newproducts that reached their first markets. A guide to PROUS SCIENCE DRUG NEWS & PERSPECTIVES is copyrighted by Prous Science . For Dialog's Redistribution and Archive policy, enter HELP ERA online. For Terms and Conditions, enter HELPTERMS 455 online.
Dialog LLC. All rights reserved. DIALOG is a registered trademark of Dialog LLC. Reg. U.S. Patent and Trademark Office.
Prous Science Drug News & Perspectives
The Year's New Drugs Section
DIALOG(R)File 455:Prous Science Drug News & Perspectives (c) 2000 J.R. Prous, S.A. All rts. reserv.
00238215 (THIS IS THE FULLTEXT) JN=, /SH, SH=
Drug News & Perspectives, The Years New Drugs Section, v7, n1, p26 DT=, LA=, RT=
DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: FullText WORD COUNT: 3,686 TEXT: Inaugurated six years ago, this annual section provides the opportunity to present from both a historical and a research perspective those molecular entities and biological drugs that were launched in various countries for the first time during the past year.
Without exceeding space limitations, information on these drugs is presented to serve as a guide to the most recent developments in drug therapy, highlighting new-generation compounds with therapeutic gains over existing drugs and new therapeutic entities arising from innovative approaches to drug research. New indications for known drugs and new formulations are also included.
According to our records, 44 new molecular entities and biological drugs and 3 diagnostic agents first reached the market in 1993, a figure that represents a decrease with respect to the previous year (Table I). During the past year, antiinfective agents represented the most active group in terms of total launches, followed by central nervous system drugs. Japan was the most active market for new products, with a total of 21 launches in 1993, representing 49% of the total of new introductions for the year.
(.) CENTRAL NERVOUS SYSTEM DRUGS Psychopharmacologic drugs Since the introduction of chlorpromazine in 1952, the dopamine D2 receptor has been the major target for antipsychotic drugs.
(.) Neurologic drugs The cholinergic hypothesis of senile dementia proposes that aging is associated with a loss of cholinergic neurotransmission, which is essential for some cognitive functions. The cholinergic hypothesis has led to the development of compounds capable of improving cholinergic transmission within the CNS.
(.) ANTIARTHRITIC DRUGS Two new NSAIDs were launched in Japan: ampiroxicam is marketed by Toyama (Nacyl) and Pfizer (Flucam), and the propionic acid derivative zaltoprofen was launched by Zeria (Peon) and Nippon Chemiphar (Soleton).
RESPIRATORY DRUGS The potent H1-receptor antagonist emedastine difumarate was launched in Japan by Kowa (Remicut) and Kanebo (Daren) for the treatment of allergic rhinitis and urticaria.
(.) CARDIOVASCULAR DRUGS Research on angiotensin-converting enzyme (ACE) inhibitors has resulted in the development of important new agents for the treatment of hypertension and heart failure.
(.) RENAL-UROLOGIC DRUGS Torasemide (Boehringer Mannheim) is a sulfonylurea loop diuretic that was introduced last year in Germany (Unat) and Italy (Toradiur) and was approved in the U.S. (Demadex) for the.
(.) DRUGS AFFECTING BLOOD COAGULATION Over the last decade, successful attempts have been made to fractionate and depolymerize heparin into fragments of various chain lengths. Low-molecular-weight heparins (LMWHs) inhibit.
(.) ENDOCRINE DRUGS Prolactin, a hormone released from the anterior pituitary, regulates lactation. Dopamine D2 agonists have proven effective in preventing or suppressing puerperal lactation, as well as in.
Prous Science Drug News & Perspectives
The Year's New Drugs Section (cont'd)
(.) METABOLIC DRUGS Osteoporosis is an important public health problem and is the cause of at least 1.2 million bone fractures in the U.S. each year. Two approaches toward bone mass manipulation have been.
(.) GASTROINTESTINAL AGENTS As part of a program aimed toward discovering new antiulcer agents with enhanced cytoprotective activity, scientists at Tanabe Seiyaku synthesized a series of dehydroabietic acid.
(.) DERMATOLOGIC DRUGS Betamethasone butyrate propionate (Antebate; Torii) was launched last year in Japan as a topical antiinflammatory corticosteroid.
(.) IMMUNOLOGIC DRUGS A new vaccine that combines Lederle's diphtheria, tetanus and pertussis (DTP) vaccine (Tri-Immunol) with Praxis Biologics' Haemophilus b conjugate vaccine (HibTITER) was launched last year.
(.) ANTIINFECTIVE AGENTS Thienamycin was isolated in 1979 from Streptomyces cattleya and was found to be highly active against almost all bacteria that are pathogenic in humans.
(.) ANTINEOPLASTIC AGENTS Cladribine (Leustatin; Ortho Biotech) was launched last year in the United States as a single intravenous treatment for hairy cell leukemia, a rare, often fatal cancer of the blood and bone.
(.) DIAGNOSTIC AGENTS Last year Shionogi launched Molecular Biosystems' Albunex injections, which are air-filled microspheres produced by sonication of human serum albumin, in Japan as a contrast agent.
(.) .Radioisotope for the diagnosis of neuroblastoma, neurocytoma and medullary cancer of the thyroid.
Copyright (c) 1994 J.R. Prous. All rights reserved.
R&D Briefs Section
DIALOG(R) File 455: Prous Science Drug News & Perspectives (c) 2000 J.R. Prous, S.A. All rts. reserv.
00268003 (THIS IS THE FULLTEXT) MEDAREX BEGINS PHASE I/II TRIAL of MDX-210 WITH G-CSF JN=, /SH, SH=
Drug News & Perspectives, R&D Briefs Section, v7, n8, P 485 DT=, LA=, RT=
DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: Fulltext WORD COUNT: 134 TEXT: Medarex Inc. announced September 8, 1994, the initiation of a phase I/II clinical trial to evaluate MDX-210, the company's Bispecific(TM) antibody-based therapeutic for the treatment of breast cancer, in combination with granulocyte colony-stimulating factor (G-CSF).
Preclinical studies indicated that this combination therapy may have the potential to increase the antitumor activity already observed in initial phase I/II clinical trials of MDX-210.
Approximately 20 patients with demonstrated resistance to conventional treatments for breast cancer will be enrolled in the trial. The phase I/II will be conducted at the University of Erlangen, Germany, under the direction of Roland Repp, M.D., one of the investigators who led the preclinical studies of the combination therapy. The goal of the phase I/II trial is to evaluate the safety and optimal biological dose of MDX-210 in combination with G-CSF.
Copyright (c) 1994 J.R. Prous. All rights reserved.
Prous Science Drug News & Perspectives
SEARCH OPTIONS
BASIC INDEX
FIELD NAME
INDEXING
SELECT EXAMPLES
1 Searchable in the Basic Index and in the Additional Indexes.
ADDITIONAL INDEXES
FIELD NAME
INDEXING
SELECT EXAMPLES
Display Includes journal name, section, volume, issue, Prous Science Drug News & Perspectives
SPECIAL FEATURES
For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP CURRENTonline.
/ENG -- English-Language Articles3
/FULLTEXT -- Full-Text Records4
/LONG -- Word Count of 1,000 words or more
/SHORT -- Word Count of less than 1,000 words
/YYYY -- Publication Year
JN, PD, PY, TI
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Search only the most recent year plus one (CURRENT1) to five (CURRENT5) years.
PREDEFINED FORMAT OPTIONS
DIALOGWEB
RECORD CONTENT
Bibliographic Citation, Word Count, and Extract Bibliographic Citation, Word Count, and Extract KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats OTHER OUTPUT OPTIONS
For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.
USER DEFINED
Display codes listed in the Search Options tables can be used to customize output.
Output can be displayed with tags identifying each display field.
DIRECT RECORD
If the accession number of a specific record is known, it can be used to display the FOR ONLINE HELP:
See HELP FIELDS 455 for searchable fields; HELP FORMAT 455 for output formats; HELP LIMIT 455 for limits; HELP RATES 455 for
cost information; HELP SORT 455 for sorts.

Source: http://library.dialog.com/bluesheets/pdf/bl0455.pdf